PER-048-06已完成未知
Multicenter, Double Blind, Randomized, Parallel Groups, Controlled with Vehicle Study to Determine the Clinical Bioequivalence of a 2% Mupirocin Topical Ointment and Bactroban Ointment in Subjects with Impetigo
Glemmark Pharnaceuticals. INC,0 个研究点目标入组 0 人开始时间: 2006年9月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1. Complete an Informed Consent Process, including signature and date of an Informed Consent Form. In the case of minors, it will be necessary for their parent or guardian to sign the Informed Consent Form. The subjects will give their assent in writing whenever possible.
- •2. All female subjects who are of reproductive age should have a negative urine pregnancy test and commit to abstinence, or use prescription contraceptives and use a contraceptive barrier device along with a spermicidal product throughout the entire duration of the study.
- •3. The subject is voluntary and able to meet the requirements of the study.
- •4. The subject has a diagnosis of impetigo.
- •5. The subject has a score of> 8 on the SIRS Cutaneous Infection Scale which is based on the sum of individual Blister scores, Exudate / Pus, Crust, Erythema / Inflammation, and Itch / Pain.
排除标准
- •1. The subject must not be less than 18 months of age at the time of
- •2. The woman who is the subject of the study should not be pregnant or breastfeeding, nor should she plan to become pregnant during the study period.
- •3. Subjects with extended blister impetigo, cellulitis, furunculosis, abscesses and chronic dermatitis should be excluded from the study. Subjects with more than three lesions should be evaluated to determine if topical therapy is appropriate.
- •4. Subjects with lesions secondary infections caused by animal, trauma, or surgery will be excluded.
- •5. Subjects who have used a test should be excluded from the study.
- •topical or systemic or antimicrobial antibiotic, or antibacterial soap within 24 hours.
- •6. Subjects with a history of renal failure or active kidney disease should be excluded from the study.
- •7. Any subject with a documented history of hypersensitivity to the investigational mupirocin product, other related agents, or who knows that he / she is allergic, hypersensitive, or for some other reason intolerant to any one, should be excluded from the study.
- •component of the study medications.
- •8. The subject should not be taking any cytotoxic, cytostatic or immunosuppressive agent, within 30 days before enrolling in the study.
- •9. All subjects with a history of treatment for alcohol or drug abuse within the last year should be excluded from the study.
- •10. The presence of any condition for which the therapy with the research product is clinically contraindicated, or of any condition that prevents the subject from participating in the study.
- •11. The subject must not have taken any experimental or investigational drug within 30 days before enrolling.
研究者
相似试验
已完成
不适用
Multicenter, Randomized, Double Blind, Parallel Group, Controlled with Placebo and Active Study, Carried Out Under Internal Blind Conditions whose Purpose is to Determine the Incidence of Gastroduodenal Ulcers in Patients Suffering from Osteoarthritis after 12 Weeks of Placebo Treatment, Low Dose of Aspirin, MK-0966 plus Low Dosage of Aspirin or Ibuprofen.-K26K26PER-067-00MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
Study to investigate the Potential Effect of Benralizumab on the antibody response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients with Severe Asthma (ALIZE)AsthmaEUCTR2016-001717-24-Outside-EU/EEAAstraZeneca AB100
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HRMylan GmbH640
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.EUCTR2015-005141-32-ITMYLAN GMBH478
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 19.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HUMylan GmbH478